Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Detection of Naturally Occurring Antibodies to PEG and PEGylated Liposomes in Plasma of Human Donor Volunteers: Version 2

Barry W. Neun  1 , Marina A. Dobrovolskaia  1
In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May. NCL Method ITA-36.
2020 Jun.
Affiliations
Free Books & Documents
Review

Detection of Naturally Occurring Antibodies to PEG and PEGylated Liposomes in Plasma of Human Donor Volunteers: Version 2

Barry W. Neun et al.
Free Books & Documents

Excerpt

Poly(ethylene glycol) (PEG) is commonly used in the pharmaceutical industry to modify recombinant proteins and nanoparticle surfaces to improve hydrophilicity and decrease their recognition by the immune system. PEGylated therapeutics and nanoparticles are generally recognized as more stealth than their un-PEGylated counterparts. Despite improved protection from immune recognition, the immune system is still able to identify these products and mount an antibody response against them. Such immune response may result in the development of anti-drug antibodies (ADA), and among antibodies specific to the biological drug or nanocarrier, include the formation of antibodies to the PEG itself. Moreover, several reports have suggested the existence of naturally occurring antibodies in the blood of healthy donor volunteers. The physiological significance of anti-PEG antibodies is unknown. However, several studies suggested that they may affect the clearance of PEGylated products (e.g., Accelerated Blood Clearance or ABC phenomenon) and contribute to complement activation and other antibody-mediated toxicities. The purpose of this protocol is to detect the presence of antibodies reactive to PEG2000, mPEG2000 and PEGylated liposomes used for delivery of the anti-cancer drug doxorubicin, also known as Doxil. The protocol can be used to assess the presence of both the naturally occurring antibodies and the antibodies induced as a result of exposure to PEGylated liposomes. The protocol can also be useful in assessing PEG and mPEG antibodies which may react with PEG present in other, non-liposomal, products.

PubMed Disclaimer

Similar articles

See all similar articles

LinkOut - more resources